JP2017530168A - 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位 - Google Patents
分娩制御物質を含有する口腔内崩壊性固形医薬投与単位 Download PDFInfo
- Publication number
- JP2017530168A JP2017530168A JP2017518256A JP2017518256A JP2017530168A JP 2017530168 A JP2017530168 A JP 2017530168A JP 2017518256 A JP2017518256 A JP 2017518256A JP 2017518256 A JP2017518256 A JP 2017518256A JP 2017530168 A JP2017530168 A JP 2017530168A
- Authority
- JP
- Japan
- Prior art keywords
- dosage unit
- weight
- orally disintegrating
- pharmaceutical dosage
- solid pharmaceutical
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000007787 solid Substances 0.000 title claims abstract description 55
- 239000000126 substance Substances 0.000 title claims abstract description 25
- 230000032696 parturition Effects 0.000 title claims description 9
- 101800000989 Oxytocin Proteins 0.000 claims abstract description 70
- XNOPRXBHLZRZKH-DSZYJQQASA-N oxytocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@H](N)C(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 XNOPRXBHLZRZKH-DSZYJQQASA-N 0.000 claims abstract description 69
- XNOPRXBHLZRZKH-UHFFFAOYSA-N Oxytocin Natural products N1C(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CC(C)C)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C(C(C)CC)NC(=O)C1CC1=CC=C(O)C=C1 XNOPRXBHLZRZKH-UHFFFAOYSA-N 0.000 claims abstract description 67
- 229960001723 oxytocin Drugs 0.000 claims abstract description 67
- 239000002245 particle Substances 0.000 claims abstract description 50
- 239000011248 coating agent Substances 0.000 claims abstract description 46
- 238000000576 coating method Methods 0.000 claims abstract description 46
- 229920001503 Glucan Polymers 0.000 claims abstract description 27
- NSTRIRCPWQHTIA-DTRKZRJBSA-N carbetocin Chemical compound C([C@H]1C(=O)N[C@H](C(N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSCCCC(=O)N1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC(C)C)C(=O)NCC(N)=O)=O)[C@@H](C)CC)C1=CC=C(OC)C=C1 NSTRIRCPWQHTIA-DTRKZRJBSA-N 0.000 claims abstract description 23
- 229960001118 carbetocin Drugs 0.000 claims abstract description 23
- 108700021293 carbetocin Proteins 0.000 claims abstract description 22
- 239000007771 core particle Substances 0.000 claims abstract description 21
- 239000004615 ingredient Substances 0.000 claims abstract description 20
- 230000003139 buffering effect Effects 0.000 claims abstract description 9
- VWXRQYYUEIYXCZ-OBIMUBPZSA-N atosiban Chemical compound C1=CC(OCC)=CC=C1C[C@@H]1C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@H](C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CCCN)C(=O)NCC(N)=O)CSSCCC(=O)N1 VWXRQYYUEIYXCZ-OBIMUBPZSA-N 0.000 claims abstract description 6
- 229960002403 atosiban Drugs 0.000 claims abstract description 6
- 108700007535 atosiban Proteins 0.000 claims abstract description 6
- 102100031951 Oxytocin-neurophysin 1 Human genes 0.000 claims abstract 4
- 239000000872 buffer Substances 0.000 claims description 26
- 239000000203 mixture Substances 0.000 claims description 20
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 17
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 15
- 229930195725 Mannitol Natural products 0.000 claims description 15
- 239000000594 mannitol Substances 0.000 claims description 15
- 235000010355 mannitol Nutrition 0.000 claims description 15
- 238000011282 treatment Methods 0.000 claims description 14
- 208000018525 Postpartum Hemorrhage Diseases 0.000 claims description 13
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 claims description 12
- 239000008101 lactose Substances 0.000 claims description 12
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 claims description 11
- 229920002307 Dextran Polymers 0.000 claims description 11
- 150000001768 cations Chemical class 0.000 claims description 9
- 229910052751 metal Inorganic materials 0.000 claims description 9
- 239000002184 metal Substances 0.000 claims description 9
- 239000012876 carrier material Substances 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 229960001375 lactose Drugs 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical group [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 4
- 239000003795 chemical substances by application Substances 0.000 claims description 4
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 3
- 229920000168 Microcrystalline cellulose Polymers 0.000 claims description 3
- 208000005107 Premature Birth Diseases 0.000 claims description 3
- 229940009098 aspartate Drugs 0.000 claims description 3
- 239000008108 microcrystalline cellulose Substances 0.000 claims description 3
- 235000019813 microcrystalline cellulose Nutrition 0.000 claims description 3
- 229940016286 microcrystalline cellulose Drugs 0.000 claims description 3
- 238000002156 mixing Methods 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 229920002785 Croscarmellose sodium Polymers 0.000 claims description 2
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 claims description 2
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 2
- 229960001681 croscarmellose sodium Drugs 0.000 claims description 2
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 claims description 2
- 229960001855 mannitol Drugs 0.000 claims description 2
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 claims description 2
- 239000000811 xylitol Substances 0.000 claims description 2
- 235000010447 xylitol Nutrition 0.000 claims description 2
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 claims description 2
- 229960002675 xylitol Drugs 0.000 claims description 2
- 239000006172 buffering agent Substances 0.000 abstract description 4
- 238000004519 manufacturing process Methods 0.000 abstract description 2
- 102400000050 Oxytocin Human genes 0.000 description 63
- 239000000843 powder Substances 0.000 description 24
- 239000003826 tablet Substances 0.000 description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 16
- 239000000243 solution Substances 0.000 description 13
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 12
- 208000037805 labour Diseases 0.000 description 12
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 11
- 239000007916 tablet composition Substances 0.000 description 11
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical class OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 10
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 9
- 238000009472 formulation Methods 0.000 description 8
- 239000003153 chemical reaction reagent Substances 0.000 description 7
- 238000007918 intramuscular administration Methods 0.000 description 7
- 238000001990 intravenous administration Methods 0.000 description 7
- 239000011668 ascorbic acid Substances 0.000 description 6
- 235000010323 ascorbic acid Nutrition 0.000 description 6
- 229960005070 ascorbic acid Drugs 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 6
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 6
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 6
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 239000003814 drug Substances 0.000 description 5
- 239000012530 fluid Substances 0.000 description 5
- 108090000765 processed proteins & peptides Proteins 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- 239000003352 sequestering agent Substances 0.000 description 5
- 208000032843 Hemorrhage Diseases 0.000 description 4
- 230000000740 bleeding effect Effects 0.000 description 4
- 239000007853 buffer solution Substances 0.000 description 4
- 150000004676 glycans Chemical class 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 239000007788 liquid Substances 0.000 description 4
- 229920001282 polysaccharide Polymers 0.000 description 4
- 239000005017 polysaccharide Substances 0.000 description 4
- 229920003109 sodium starch glycolate Polymers 0.000 description 4
- 229940079832 sodium starch glycolate Drugs 0.000 description 4
- 239000008109 sodium starch glycolate Substances 0.000 description 4
- 239000007921 spray Substances 0.000 description 4
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical compound [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 description 4
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- 208000000091 Maternal Death Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000011247 coating layer Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 238000007596 consolidation process Methods 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- MVPICKVDHDWCJQ-UHFFFAOYSA-N ethyl 3-pyrrolidin-1-ylpropanoate Chemical compound CCOC(=O)CCN1CCCC1 MVPICKVDHDWCJQ-UHFFFAOYSA-N 0.000 description 3
- 239000008103 glucose Substances 0.000 description 3
- 239000007800 oxidant agent Substances 0.000 description 3
- 239000000825 pharmaceutical preparation Substances 0.000 description 3
- 229940127557 pharmaceutical product Drugs 0.000 description 3
- 230000000144 pharmacologic effect Effects 0.000 description 3
- 229940045902 sodium stearyl fumarate Drugs 0.000 description 3
- 238000013112 stability test Methods 0.000 description 3
- 239000006190 sub-lingual tablet Substances 0.000 description 3
- 150000005846 sugar alcohols Chemical class 0.000 description 3
- 150000003573 thiols Chemical class 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 239000011701 zinc Substances 0.000 description 3
- 229920000310 Alpha glucan Polymers 0.000 description 2
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 2
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 2
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 238000006243 chemical reaction Methods 0.000 description 2
- 230000035606 childbirth Effects 0.000 description 2
- 230000003247 decreasing effect Effects 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 229940119744 dextran 40 Drugs 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Chemical compound OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 2
- 230000009931 harmful effect Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 229910021645 metal ion Inorganic materials 0.000 description 2
- 229930182817 methionine Natural products 0.000 description 2
- 230000001590 oxidative effect Effects 0.000 description 2
- 229940030215 pitocin Drugs 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000035935 pregnancy Effects 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- -1 small molecule compounds Chemical class 0.000 description 2
- 239000001509 sodium citrate Substances 0.000 description 2
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000011592 zinc chloride Substances 0.000 description 2
- 235000005074 zinc chloride Nutrition 0.000 description 2
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 description 1
- 229920000945 Amylopectin Polymers 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 229920002498 Beta-glucan Polymers 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 150000000996 L-ascorbic acids Chemical class 0.000 description 1
- FFFHZYDWPBMWHY-VKHMYHEASA-N L-homocysteine Chemical compound OC(=O)[C@@H](N)CCS FFFHZYDWPBMWHY-VKHMYHEASA-N 0.000 description 1
- 241000192130 Leuconostoc mesenteroides Species 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920000881 Modified starch Polymers 0.000 description 1
- 241000194019 Streptococcus mutans Species 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 206010046788 Uterine haemorrhage Diseases 0.000 description 1
- 206010046910 Vaginal haemorrhage Diseases 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229940024606 amino acid Drugs 0.000 description 1
- 235000001014 amino acid Nutrition 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 150000001413 amino acids Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000013011 aqueous formulation Substances 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000006189 buccal tablet Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000007891 compressed tablet Substances 0.000 description 1
- 238000007906 compression Methods 0.000 description 1
- 230000006835 compression Effects 0.000 description 1
- XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 125000000151 cysteine group Chemical group N[C@@H](CS)C(=O)* 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 125000002228 disulfide group Chemical group 0.000 description 1
- VHJLVAABSRFDPM-QWWZWVQMSA-N dithiothreitol Chemical compound SC[C@@H](O)[C@H](O)CS VHJLVAABSRFDPM-QWWZWVQMSA-N 0.000 description 1
- 239000008298 dragée Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000010408 film Substances 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 210000004195 gingiva Anatomy 0.000 description 1
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- ICIWUVCWSCSTAQ-UHFFFAOYSA-N iodic acid Chemical class OI(=O)=O ICIWUVCWSCSTAQ-UHFFFAOYSA-N 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000012669 liquid formulation Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000008774 maternal effect Effects 0.000 description 1
- 239000002906 medical waste Substances 0.000 description 1
- 239000002858 neurotransmitter agent Substances 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 239000006174 pH buffer Substances 0.000 description 1
- 230000036961 partial effect Effects 0.000 description 1
- JRKICGRDRMAZLK-UHFFFAOYSA-L persulfate group Chemical group S(=O)(=O)([O-])OOS(=O)(=O)[O-] JRKICGRDRMAZLK-UHFFFAOYSA-L 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 210000001883 posterior pituitary gland Anatomy 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 125000003396 thiol group Chemical group [H]S* 0.000 description 1
- 150000007944 thiolates Chemical class 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
- 230000001720 vestibular Effects 0.000 description 1
- DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/08—Peptides having 5 to 11 amino acids
- A61K38/095—Oxytocins; Vasopressins; Related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
- A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/06—Antiabortive agents; Labour repressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Immunology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Reproductive Health (AREA)
- Endocrinology (AREA)
- Inorganic Chemistry (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
50〜99重量%のコア粒子、及び上記コア粒子を包む、1〜50重量%のコーティングを含む、5〜100重量%のコーティングされた粒子であり、上記コーティングが、
0.01〜10重量%の、オキシトシン、カルベトシン、アトシバン及びこれらの組合せから選択される分娩制御物質、
5〜50重量%の緩衝剤、
15〜80重量%の分枝状グルカン、
0〜78重量%の他の、医薬として許容される成分
からなる、コーティングされた粒子と、
0〜95重量%の1種又は複数の医薬として許容される賦形剤と
からなり、少なくとも20μgの分娩制御物質を含み、pH緩衝範囲が3.5〜5.7である、口腔内崩壊性固形医薬投与単位を提供する。
a)時間温度インジケータ(TTI)でパッケージされたユニジェクト(Uniject)(登録商標)装置を介してIM送達されるオキシトシン
b)より熱安定な液状オキシトシン製剤
c)IM又はIV注射のために滅菌水で再溶解される、凍結乾燥された熱安定オキシトシン
d)エアロゾルの送達及び吸入のための熱安定な粉末化オキシトシン製剤。
50〜99重量%のコア粒子、及び上記コア粒子を包む、1〜50重量%のコーティングを含む、5〜100重量%のコーティングされた粒子であり、前記コーティングが、
0.01〜10重量%の、オキシトシン、カルベトシン、アトシバン及びこれらの組合せから選択される分娩制御物質、
5〜50重量%の緩衝剤、
15〜80重量%の分枝状グルカン、
0〜78重量%の他の、医薬として許容される成分
からなる、コーティングされた粒子と、
0〜95重量%の1種又は複数の医薬として許容される賦形剤と
からなり、少なくとも20μgの分娩制御物質を含み、pH緩衝範囲が3.5〜5.7である、口腔内崩壊性固形医薬投与単位に関する。
PCS、緩衝剤、分枝状グルカン、及び任意選択で1種又は複数の他の医薬として許容される成分を含む水溶液を用意するステップと、
上記水溶液を担体の粒子と合わせて、コア粒子、並びに分娩制御物質、緩衝剤、分枝状グルカン、及び任意選択で1種又は複数の他の医薬として許容される成分を含有するコーティングを含む、コーティングされた粒子を生成するステップと、
上記コーティングされた粒子を、1種又は複数の医薬として許容される賦形剤と混合するステップと、
混合物を固形投与単位に形成するステップと
を含む、方法に関する。
50〜99重量%のコア粒子、及び上記コア粒子を包む、1〜50重量%のコーティングを含む、5〜100重量%のコーティングされた粒子であり、前記コーティングが、
0.01〜10重量%の、オキシトシン、カルベトシン、アトシバン及びこれらの組合せから選択される分娩制御物質、
5〜50重量%の緩衝剤、
15〜80重量%の分枝状グルカン、
0〜78重量%の他の、医薬として許容される成分
からなる、コーティングされた粒子と、
0〜95重量%の1種又は複数の医薬として許容される賦形剤と
からなり、少なくとも20μgの分娩制御物質を含み、pH緩衝範囲が3.5〜5.7である、口腔内崩壊性固形医薬投与単位に関する。
分娩制御物質、緩衝剤、分枝状グルカン、及び任意選択で1種又は複数の他の医薬として許容される成分を含む水溶液を用意するステップと、
上記水溶液を担体の粒子と合わせて、コア粒子、並びに分娩制御物質、緩衝剤、分枝状グルカン、及び任意選択で1種又は複数の他の医薬として許容される成分を含有するコーティングを含む、コーティングされた粒子を生成するステップと、
上記コーティングされた粒子を、1種又は複数の医薬として許容される賦形剤と混合するステップと、
混合物を固形投与単位に形成するステップと
を含む、方法に関する。
オキシトシン含有のコーティングされた粉末を、オキシトシン、クエン酸、クエン酸ナトリウム、塩化亜鉛、加水分解デキストラン(デキストラン40)及びヒドロキシプロピルメチルセルロース(HPMC)の水溶液を、マンニトール粉末へ、流動床乾燥機中で噴霧することによって調製した。噴霧溶液を、表1に示す成分を、示された量で、蒸留水200mlへ加え、pHを4.6に調節する(HCl又はNaOHを使用)ことによって調製した。
実施例1を繰り返し、但し今回は、マンニトール粉末へ噴霧する噴霧溶液を、より多量とする。
実施例1を繰り返し、但し今回は、マンニトール粉末へ噴霧する噴霧溶液を、実施例2におけるものよりも更に多量とする。
オキシトシン含有のコーティングされた粉末を、オキシトシン、クエン酸、クエン酸ナトリウム、塩化亜鉛及び分枝状グルカンの4種の異なる水溶液をマンニトール粉末へ高せん断粉砕機中で噴霧して続いて40℃にて乾燥させることによって調製した。4種の異なる分枝状グルカン、すなわちデキストラン20、デキストラン40、デキストラン60及びアルファ化デンプンを試験した。噴霧溶液を、先に述べた成分を脱塩水に加えてpHを4.6に調節する(HCl又はNaOHを使用)ことによって調製した。使用したマンニトール粉末は、質量加重平均直径が100μmであった。
貯蔵溶液200mlを、表1に示す配合に基づいて調製した。使用した水は、室温(およそ20℃)とした。オキシトシン以外の固形成分を容器へ導入した。必要とする水のうちのおよそ90%を加え、続いて全ての固体が溶解するまで磁気撹拌機で連続撹拌した。オキシトシンを加え、溶液のpHを、1MのHCl又は1MのNaOHで、必要とするpH値(表1を参照されたい)まで設定した。水の残りの量を加えて混合した。該溶液を2〜8℃にて貯蔵した。
Claims (15)
- 重量が50〜1000mgである口腔内崩壊性固形医薬投与単位であって、
50〜99重量%のコア粒子、及び前記コア粒子を包む、1〜50重量%のコーティングを含む、5〜100重量%のコーティングされた粒子であり、前記コーティングが、
0.01〜10重量%の、オキシトシン、カルベトシン、アトシバン及びこれらの組合せから選択される分娩制御物質、
5〜50重量%の緩衝剤、
15〜80重量%の分枝状グルカン、
0〜78重量%の他の、医薬として許容される成分
からなる、コーティングされた粒子と、
0〜95重量%の1種又は複数の医薬として許容される賦形剤と
からなり、少なくとも20μgの分娩制御物質を含み、pH緩衝範囲が3.5〜5.7である、
口腔内崩壊性固形医薬投与単位。 - 緩衝剤のpH緩衝範囲が4.0〜5.5である、請求項1に記載の口腔内崩壊性固形医薬投与単位。
- 緩衝剤が、クエン酸塩、酢酸塩、アスパラギン酸塩及びこれらの組合せから選択される、請求項1又は2に記載の口腔内崩壊性固形医薬投与単位。
- 分枝状グルカンが、平均分子量が10〜200kDaの範囲にある加水分解デキストランである、請求項1〜3のいずれか一項に記載の口腔内崩壊性固形医薬投与単位。
- 分娩制御物質が、オキシトシンである、請求項1〜4のいずれか一項に記載の口腔内崩壊性固形医薬投与単位。
- 分娩制御物質が、カルベトシンである、請求項1〜5のいずれか一項に記載の口腔内崩壊性固形医薬投与単位。
- 分娩制御物質が、アトシバンである、請求項1〜6のいずれか一項に記載の口腔内崩壊性固形医薬投与単位。
- コーティングが、0.02〜10重量%の二価金属カチオンを含有する、請求項1〜7のいずれか一項に記載の口腔内崩壊性固形医薬投与単位。
- 二価金属カチオン及び分娩制御物質が、コーティング中に、モル比5:1〜1000:1、好ましくはモル比10:1〜300:1で存在する、請求項8に記載の口腔内崩壊性固形医薬投与単位。
- コア粒子が、少なくとも50重量%、より好ましくは少なくとも80重量%の、マンニトール、ラクトース、セルロース及びこれらの組合せから選択される担体材料を含有する、請求項1〜9のいずれか一項に記載の口腔内崩壊性固形医薬投与単位。
- 1種又は複数の医薬として許容される賦形剤が、ラクトース、マンニトール、キシリトール、微結晶セルロース、クロスカルメロースナトリウム及びこれらの組合せから選択される、請求項1〜10のいずれか一項に記載の口腔内崩壊性固形医薬投与単位。
- 医学的治療における使用のための投与単位であって、前記治療が、請求項1〜11のいずれか一項に記載の投与単位の、頬側、舌下又は唇下投与を含む、投与単位。
- 分娩後出血の治療における使用のための、オキシトシン、カルベトシン及びこれらの組合せから選択される分娩制御物質を含有する、請求項12に記載の投与単位。
- 早産を予防する又は止めるための使用のための、アトシバンを含有する、請求項12に記載の投与単位。
- 請求項1〜11のいずれか一項に記載の固形投与単位を調製する方法であって、
分娩制御物質、緩衝剤、分枝状グルカン、及び任意選択で1種又は複数の他の医薬として許容される成分を含む水溶液を用意するステップと、
前記水溶液を担体の粒子と合わせて、コア粒子、並びに分娩制御物質、緩衝剤、分枝状グルカン、及び任意選択で1種又は複数の他の医薬として許容される成分を含有するコーティングを含む、コーティングされた粒子を生成するステップと、
前記コーティングされた粒子を、1種又は複数の医薬として許容される賦形剤と混合するステップと、
混合物を固形投与単位に形成するステップと
を含む、方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP14187354 | 2014-10-01 | ||
EP14187354.7 | 2014-10-01 | ||
PCT/NL2015/050673 WO2016053091A1 (en) | 2014-10-01 | 2015-09-29 | Orally disintegrating solid pharmaceutical dosage unit containing a partus control substance |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2017530168A true JP2017530168A (ja) | 2017-10-12 |
JP6607508B2 JP6607508B2 (ja) | 2019-11-20 |
Family
ID=51660353
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2017518256A Active JP6607508B2 (ja) | 2014-10-01 | 2015-09-29 | 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位 |
Country Status (10)
Country | Link |
---|---|
US (1) | US10172913B2 (ja) |
EP (1) | EP3200764B1 (ja) |
JP (1) | JP6607508B2 (ja) |
CN (1) | CN107106640B (ja) |
ES (1) | ES2821822T3 (ja) |
HU (1) | HUE051974T2 (ja) |
PL (1) | PL3200764T3 (ja) |
RU (1) | RU2719416C2 (ja) |
WO (1) | WO2016053091A1 (ja) |
ZA (1) | ZA201702241B (ja) |
Families Citing this family (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TW202031283A (zh) | 2018-09-20 | 2020-09-01 | 馬克 C 曼寧 | 穩定卡貝縮宮素鼻內製劑 |
EP3852724A4 (en) | 2018-09-20 | 2022-07-06 | Levo Therapeutics, Inc. | CARBETOCIN DRUG PRODUCT AND PROCESS FOR ITS MANUFACTURE |
CN110507811A (zh) * | 2019-09-17 | 2019-11-29 | 南京赛弗斯医药科技有限公司 | 一种3d打印卡贝缩宫素舌下口崩片及其制备方法 |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009506071A (ja) * | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
WO2010030180A2 (en) * | 2008-09-09 | 2010-03-18 | Rijksuniversiteit Groningen | Peptide formulations and uses thereof |
CN102580057A (zh) * | 2012-03-14 | 2012-07-18 | 南京先宇科技有限公司 | 含有麦角新碱与缩宫素类似物的药物组合物及制备方法 |
JP2013249305A (ja) * | 2006-01-27 | 2013-12-12 | Aptalis Pharmatech Inc | 弱塩基性選択性セロトニン5−ht3遮断剤および有機酸を含む薬物送達系 |
CN104055732A (zh) * | 2014-07-10 | 2014-09-24 | 成都天台山制药有限公司 | 卡贝缩宫素注射液和制法 |
Family Cites Families (10)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AT251762B (de) | 1962-07-19 | 1967-01-25 | Sanabo Fabrik Chemischer Und P | Verfahren zur Herstellung von stabilen, lagerfähigen Lingual- bzw. Bukkaltabletten von Oxytocin |
NL7309392A (ja) | 1972-07-10 | 1974-01-14 | ||
EP0493380B1 (en) * | 1989-09-05 | 1997-10-29 | University Of Utah Research Institute | Method and compositions for noninvasive dose-to-effect administration of lipophilic drugs |
SE9400918L (sv) * | 1994-03-18 | 1995-09-19 | Anne Fjellstad Paulsen | Stabiliserad komposition för oral administrering av peptider |
GB0221712D0 (en) * | 2002-09-19 | 2002-10-30 | Ardana Bioscience Ltd | Methods of treatment |
ES2414084T3 (es) * | 2003-02-24 | 2013-07-18 | Pharmaceutical Productions Inc. | Sistema de administración de fármacos por vía transmucosa |
GB0903559D0 (en) | 2009-03-02 | 2009-04-08 | Univ London Pharmacy | Oral delivery of hydrophilic drugs to the brain |
JO3400B1 (ar) | 2010-09-30 | 2019-10-20 | Ferring Bv | مركب صيدلاني من كاربيتوسين |
CN102146122A (zh) * | 2010-11-12 | 2011-08-10 | 深圳市健元医药科技有限公司 | 一种具有宫缩作用药物的生产工艺 |
CN103830720A (zh) * | 2014-03-25 | 2014-06-04 | 深圳翰宇药业股份有限公司 | 一种含缩宫素的药物组合物 |
-
2015
- 2015-09-29 CN CN201580054014.4A patent/CN107106640B/zh active Active
- 2015-09-29 HU HUE15813588A patent/HUE051974T2/hu unknown
- 2015-09-29 US US15/516,127 patent/US10172913B2/en active Active
- 2015-09-29 PL PL15813588T patent/PL3200764T3/pl unknown
- 2015-09-29 WO PCT/NL2015/050673 patent/WO2016053091A1/en active Application Filing
- 2015-09-29 JP JP2017518256A patent/JP6607508B2/ja active Active
- 2015-09-29 ES ES15813588T patent/ES2821822T3/es active Active
- 2015-09-29 RU RU2017114678A patent/RU2719416C2/ru active
- 2015-09-29 EP EP15813588.9A patent/EP3200764B1/en active Active
-
2017
- 2017-03-30 ZA ZA2017/02241A patent/ZA201702241B/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2009506071A (ja) * | 2005-08-26 | 2009-02-12 | ザ・ボード・オブ・トラスティーズ・オブ・ザ・レランド・スタンフォード・ジュニア・ユニバーシティ | オキシトシンの投与による頭痛の処置のための方法 |
JP2013249305A (ja) * | 2006-01-27 | 2013-12-12 | Aptalis Pharmatech Inc | 弱塩基性選択性セロトニン5−ht3遮断剤および有機酸を含む薬物送達系 |
WO2010030180A2 (en) * | 2008-09-09 | 2010-03-18 | Rijksuniversiteit Groningen | Peptide formulations and uses thereof |
CN102580057A (zh) * | 2012-03-14 | 2012-07-18 | 南京先宇科技有限公司 | 含有麦角新碱与缩宫素类似物的药物组合物及制备方法 |
CN104055732A (zh) * | 2014-07-10 | 2014-09-24 | 成都天台山制药有限公司 | 卡贝缩宫素注射液和制法 |
Non-Patent Citations (1)
Title |
---|
HEAT-STABLE SUBLINGUAL OXYTOCIN FOR THE PREVENTION AND TREATMENT OF POSTPARTUM HEMORRHAGE(ONLINE)RET, JPN6019021121, May 2014 (2014-05-01), ISSN: 0004050669 * |
Also Published As
Publication number | Publication date |
---|---|
RU2017114678A3 (ja) | 2019-04-29 |
CN107106640B (zh) | 2021-06-15 |
EP3200764B1 (en) | 2020-07-22 |
HUE051974T2 (hu) | 2021-04-28 |
CN107106640A (zh) | 2017-08-29 |
US10172913B2 (en) | 2019-01-08 |
JP6607508B2 (ja) | 2019-11-20 |
WO2016053091A1 (en) | 2016-04-07 |
BR112017006585A2 (pt) | 2017-12-19 |
ES2821822T3 (es) | 2021-04-27 |
RU2719416C2 (ru) | 2020-04-17 |
PL3200764T3 (pl) | 2020-12-28 |
EP3200764A1 (en) | 2017-08-09 |
US20170304394A1 (en) | 2017-10-26 |
ZA201702241B (en) | 2018-12-19 |
RU2017114678A (ru) | 2018-11-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20200297689A1 (en) | Ferric citrate dosage forms | |
FI93608B (fi) | Menetelmä ksantaanikumia sisältävän, kiinteän lääkevalmisteen valmistamiseksi | |
RU2678695C2 (ru) | Композиции перорально распадающихся таблеток, содержащие кортикостероиды, для лечения эозинофильного эзофагита | |
JP6607508B2 (ja) | 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位 | |
JP6607509B2 (ja) | 分娩制御物質を含有する口腔内崩壊性固形医薬投与単位 | |
WO2005084703A1 (ja) | 徐放性の口腔用組成物 | |
JP2016145187A (ja) | ゲル組成物及びその製造方法 | |
JP4122544B2 (ja) | 錠剤組成物 | |
BR112017006585B1 (pt) | Unidade de dosagem farmacêutica sólida que desintegra oralmente contendo uma substância de controle de parto | |
BR112017006588B1 (pt) | Unidade de dosagem farmacêutica sólida que desintegra oralmente contendo uma substância de controle de parto | |
CN108553439B (zh) | 一种含s-羧甲基-l-半胱氨酸的肠溶片剂 | |
JP5626698B1 (ja) | カルシウム低吸収型経口リン吸着剤 | |
TWI429428B (zh) | 檸檬酸鐵劑型 | |
JP2021520397A (ja) | 甲状腺ホルモンを含む吸入用の薬学的乾燥粉末組成物 | |
TW201945035A (zh) | 包含甲狀腺激素之用於吸入劑的醫藥乾燥粉末組成物 | |
WO2019059172A1 (ja) | 過多月経患者及び/又は過多月経を伴う婦人科疾患を有する患者における鉄欠乏性貧血の予防及び/又は治療におけるクエン酸第二鉄の使用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A529 | Written submission of copy of amendment under article 34 pct |
Free format text: JAPANESE INTERMEDIATE CODE: A529 Effective date: 20170529 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20170714 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20180927 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20190529 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20190611 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190830 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20190917 |
|
RD04 | Notification of resignation of power of attorney |
Free format text: JAPANESE INTERMEDIATE CODE: A7424 Effective date: 20190920 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20191011 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6607508 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |